ArticleBiology direct2026
Polystyrene nanoplastics induce size-associated oxidative-inflammatory stress, hepatic insulin-signaling impairment and metabolic disturbances in normal and diabetic mice.
Article in Biology direct, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
backgroundNanoplastics are emerging pollutants that can cross biological barriers and perturb metabolic homeostasis. Polystyrene nanoplastics (PS-NPs) are frequently detected in food and drinking water; however, their size-dependent metabolic effects and the modifying role of pre-existing diabetes remain incompletely understood. This study aimed to investigate whether subchronic oral exposure to PS-NPs of different particle sizes altered hepatic insulin signaling and glucose-lipid homeostasis in normal and diabetic mice, and whether oxidative-inflammatory imbalance was associated with these responses.
resultsWe found that PS-NP exposure induced size-dependent disturbances in metabolic and hepatic signaling endpoints. Among the tested particle sizes, 25 nm PS-NPs generally showed the largest apparent changes across several inflammatory, oxidative-stress, glycemic and insulin-signaling outcomes, although direct between-size differences were not uniformly established for all endpoints. PS-NP exposure increased serum levels of inflammatory cytokines (IL-6, CRP and TNF-α) and altered hepatic oxidative-stress markers, including the lipid peroxidation marker malondialdehyde (MDA) and antioxidant enzyme activities (CAT, SOD and GSH-Px), suggesting systemic inflammatory activation accompanied by hepatic oxidative-stress imbalance. These changes were associated with suppression of the hepatic IRS1-AKT-PPARγ axis and downregulation of GLUT4 expression, consistent with impaired insulin signaling and metabolic regulation. Compared with normal mice, diabetic mice exhibited exacerbated oxidative stress, inflammatory activation, and metabolic disturbance upon PS-NP exposure, suggesting higher susceptibility of metabolically compromised hosts to PS-NPs. Exploratory SEM provided supportive evidence for an association between oxidative-inflammatory imbalance and hepatic insulin-signaling impairment, while downstream links to systemic metabolic disturbance require further validation. Exploratory multivariate analyses, including principal component analysis (PCA), linear discriminant analysis (LDA), and random forest (RF), suggested response patterns associated with metabolic background and particle size, but these analyses should be interpreted as supportive pattern-recognition tools rather than validated predictive models.
conclusionsThis study suggests that PS-NPs may act as metabolic stressors under the present experimental conditions, with their effects influenced by particle size and host metabolic background. By integrating classical toxicological methods with exploratory computational modeling, our findings provide mechanistic clues and preliminary data-driven evidence that PS-NP exposure may be associated with hepatic insulin-signaling impairment and metabolic disturbance, underscoring the need to assess nanomaterial safety in metabolically vulnerable populations.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.